COVID-19 and Hereditary Angioedema in Children
Table of Contents
As of August 1, 2025, the world continues to grapple with the lingering effects of the COVID-19 pandemic, not only in terms of public health but also in its profound impact on chronic conditions. Recent medical literature highlights how the virus has, in some instances, exacerbated pre-existing health challenges, presenting new complexities for both patients and healthcare providers.One such area of emerging concern is the potential for COVID-19 to trigger or worsen hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent, unpredictable swelling episodes. This article delves into the intricate relationship between HAE and the pandemic, offering a foundational understanding of the condition and exploring the latest insights into managing its flares in the post-pandemic era.
Understanding Hereditary Angioedema: A Rare Genetic Condition
Hereditary Angioedema (HAE) is a genetic disorder that affects approximately 1 in 10,000 to 1 in 50,000 people worldwide.It is indeed caused by a deficiency or dysfunction of the C1 inhibitor (C1-INH) protein, which plays a crucial role in regulating the bodyS inflammatory response. When C1-INH is not functioning correctly, a substance called bradykinin is overproduced. Bradykinin is a peptide that causes blood vessels to leak fluid into surrounding tissues, leading to swelling.
The Genetic Basis of HAE
HAE is an autosomal dominant disorder, meaning that a person only needs to inherit one copy of the mutated gene from one parent to develop the condition. In most cases (about 80%), HAE is inherited from a parent who also has the condition. However, in about 20% of cases, HAE arises from a new genetic mutation (de novo mutation) in an individual with no family history of the disorder.
There are several types of HAE, primarily classified based on the underlying genetic defect:
HAE Type I: This is the most common type, accounting for about 85% of all cases. Individuals with HAE Type I have a quantitative deficiency of C1-INH,meaning their bodies produce too little of the protein.
HAE Type II: This type accounts for about 15% of cases. Individuals with HAE Type II produce normal amounts of C1-INH, but the protein is dysfunctional and does not work properly.
HAE with Normal C1-INH (HAE-nC1-INH) or Factor XII (FXII) Deficiency: This less common form of HAE is associated with mutations in the gene for Factor XII, a protein involved in blood clotting. The exact mechanism by which FXII mutations lead to angioedema is still being researched, but it is believed to involve the kallikrein-kinin system, similar to HAE Types I and II.
Symptoms and Triggers of HAE Flares
The hallmark symptom of HAE is recurrent,non-itchy,non-pitting swelling (angioedema) that can affect various parts of the body. These episodes, known as flares, can be unpredictable and vary in severity. Common sites for swelling include:
Extremities: Hands, feet, arms, and legs.
Face: Lips, eyelids, and tongue.
Abdomen: Leading to severe abdominal pain, nausea, vomiting, and diarrhea, often mimicking surgical emergencies.
airways: Swelling of the larynx or tongue can be life-threatening, causing airway obstruction.
HAE flares can be triggered by a variety of factors, including:
Physical Trauma: Minor injuries, dental procedures, surgery.
emotional Stress: Notable psychological distress.
Infections: Viral or bacterial infections.
Hormonal changes: Puberty, menstruation, pregnancy, and hormone replacement therapy. Certain Medications: ACE inhibitors, NSAIDs, and some oral contraceptives.
The COVID-19 Pandemic and its Impact on HAE
The emergence of COVID-19 presented a new layer of complexity for individuals living with HAE. The virus itself, and the body’s response to it, can act as potent triggers for HAE flares.